Specialty medical injectable drug program updates: Saphnelo™

Please review the following table to determine changes to our specialty medical injectable drug programs.

Drug name Treatment uses Summary of changes
Saphnelo(anifrolumab-fnia) Indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE).

Add notification/prior authorization requirement and Site of Care*.

Add preferred product.

  • Saphnelo will be non-preferred
  • Preferred product: Benlysta® (belimumab)

*Notification/prior authorization and Site of Care requirements previously communicated in October 2021 newsfeed.

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member’s eligibility changes. Providers don’t need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.

More updates for your clients

New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.

Important, required notices for products, plans, forms and more.

Need-to-know operational announcements for you and your clients.

Footnotes

Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230-ICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.